Long-term outcome of everolimus treatment in transplant patients

Transplant Research and Risk Management

Volumn 3, Issue , 2011, Pages 77-90

  Salvadori, Maurizio ^a   Bertoni, Elisabetta ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

CNI minimization; CNI withdrawal; Everolimus; Heart transplantation; Renal transplantation

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN; CYTOCHROME P450 3A4; EVEROLIMUS; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS;

ACUTE GRAFT REJECTION; ANEMIA; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ATHEROSCLEROSIS; BINDING AFFINITY; CARDIAC ALLOGRAFT VASCULOPATHY; CELL CYCLE ARREST; CHRONIC GRAFT REJECTION; CREATININE CLEARANCE; CYTOMEGALOVIRUS INFECTION; DEATH; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SUBSTITUTION; DRUG TARGETING; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD DRUG INTERACTION; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; HEART PROTECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OBESITY; PERIPHERAL EDEMA; PHARMACODYNAMICS; PLASMA PROTEIN BINDING; PROTEINURIA; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; STEADY STATE; TREATMENT DURATION; WOUND HEALING; WOUND HEALING IMPAIRMENT;

EID: 84861722256     PISSN: None     EISSN: 11791616     Source Type: Journal    
DOI: 10.2147/TRRM.S12212     Document Type: Review

References (58)

1. Meier-Kriesche HU, Schold HD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant. 2004;4: 378-383.
2. Gjertson DW. Survival trends in long-term first cadaver-donor kidney transplants. Clin Transpl. 1991:225-235.
3. Meier-Kriesche HU, Schold JS, Kaplan B. Long term renal allograft survival: Have we made a significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant. 2004;4: 1289-1295.
4. Nankivell BJ, Burrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med. 2003;349:2326-2333.
5. Abramowicz D, Manas D, Lao M, et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: A randomized, controlled study. Transplantation. 2002;74:1725-1734.
6. Ekberg H, Grinyò J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: The Caesar study. Am J Transplant. 2007;7: 560-570.
7. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med. 2007; 356:2271-2281.
8. Wullschleger S, Loewith R, Hall MN. MTOR signalling in growth and metabolism. Cell. 2006;124:471-484.
9. Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs. 2007;67:369-391.
10. Kirchner GI, Meier-Wiedenbach I, Manns M P. Clinical pharmacokinet-ics of everolimus. Clin Pharmacokinet. 2004;43:83-95.
11. MacDonald AS. Use of mTOR inhibitors in human organ transplantation. Exper Rev Clin Immunol. 2007;3:423-436.
12. Kovarik JM, Kahan BD, Kaplan B, et al. Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: Pharmacokinetics, exposure-response relationships, and influence on cyclosporine. Clin Pharmacol Ther. 2001;69: 48-56.
13. Kovarik JM, Kaplan B, Tedesco Silva H, et al. Pharmacokinetics of an everolimus-cyclosporine regimen over the first 6 months after kidney transplantation. Am J Transplant. 2003;3:606-613.
14. Kovarik JM, Eisen H, Dorent R, et al. Everolimus in de novo cardiac transplantation: Pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. J Heart Lung Transplant. 2003;22: 1117-1125.
15. Neumayer HH, Paradis K, Korn A, et al. Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients. Br J Clin Pharmacol. 1999;48:694-703.
16. Budde K, Neumayer HH, Lehne G, et al. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients. Nephrol Dial Transplant. 2004;19:2606-2614.
17. Kovarik JM, Hartmann S, Figuiredo J, et al. Effect of food on everoli-mus absorption: Quantification in healthy subjects and a confrmatory screening in patients with renal transplants. Pharmacotherapy. 2002;22: 154-159.
18. Serkova N, Hausen B, Berry GJ, et al. Tissue distribution and clinical monitoring of the novel macrolide SDZ-RAD and its metabolites in monkey lung transplant recipients: Interaction with cyclosporine. J Pharmacol Exp Ther. 2000;294:323-332.
19. Nashan B. Early clinical experience with a novel rapamycin derivative. Ther Drug Monit. 2002;24:53-58.
20. Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD: A new rapamycin derivative, synergy with cyclosporine. Transplantation. 1997;64: 32-35.
21. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD: A new rapamy-cin derivative, pharmacological properties in vitro and in vivo. Transplantation. 1997;64:36-42.
22. Hausen B, Gummert J, Berry GJ, et al. Prevention of acute allograft rejection in nonhuman primate lung transplant recipients: Induction with chimeric anti-interleukin-2 receptor monoclonal antibody improves the tolerability and potentiates the immunosuppressive activity of a regimen using low doses of both microemulsion cyclosporine and 40-O-(2-hydroxyethyl)-rapamycin. Transplantation. 2000;69:76-86.
23. Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T. 156 Study Group. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: A three-year phase II, randomized, multi center, open label study. Transplantation. 2004;78:1332-1340.
24. Vitko S, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation. 2004;78:1532-1540.
25. Vitko S, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2005;5:2521-2530.
26. Lorber MI, Mulgaonkar S, Butt KM, et al. Everolimus versus myco-phenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multi center, phase III study. Transplantation. 2005;80:244-252.
27. Vitko S, Tedesco H, Eris J, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant. 2004;4:626-635.
28. Salvadori M, Scolari M P, Bertoni E, et al. Everolimus with very low-exposure cyclosporine A in de novo kidney transplantation: A multi center, randomized, controlled trial. Transplantation. 2009;88:1194-1202.
29. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: An open-label, randomised, controlled trial. Lancet. 2011;377:837-847.
30. Lorber MI, Ponticelli C, Whelchel J, et al. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data. Clin Transplant. 2005;19:145-152.
31. Sanchez-Fructuoso AI. Everolimus: An update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol. 2008;4;807-818.
32. Pascual J. The use of everolimus in renal-transplant patients. Int J Nephrol Renovasc Dis. 2009;2:9-21.
33. Tedesco Silva H Jr, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal transplant recipients. Am J Transplant. 2010;10:1-13.
34. Bertoni E, Larti A, Rosso G, Zanazzi M, Di Maria L, Salvadori M. Good outcomes with cyclosporine very low exposure with everolimus high exposure in renal transplant patients. J Nephrol. January 14, 2011. [Epub ahead of print].
35. Chan L, Greenstein S, Hardy MA, et al. Multi center, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation. 2008;85:821-826.
36. Pascual J, del Castillo D, Cabello M, et al. Interaction between everoli-mus and tacrolimus in renal transplant recipients: A pharmacokinetic controlled trial. Transplantation. 2010;89:994-1000.
37. Tedesco-Silva H Jr, Rosso Felipe C, de Sandes Freitas T V, Pontello Cristeli M, Araùjo Rodrigues C, Medina Pestana JO. Impact of everolimus: Update on immunosuppressive therapy strategies and patient outcomes after renal transplantation. Transplant Research and Risk Management. 2011;3:9-29.
38. Schuler W, Sedrani R, Cottens S, et al. SDV RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation. 1997;64:36-42.
39. Smith MS, Bentz GL, Smith PM, Bivins ER, Yurochko AD. HCMV activates PI(3)K in monocytes and promotes monocyte motility and trans-endothelial migration in a PI(3)K-dependent manner. J Leukoc Biol. 2004;76:65-76.
40. Fishman JA, Emery V, Freeman R, et al. Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant. 2007;21:149-158.
41. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol. 2006;17:581-589.
42. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomized, placebo-controlled phase III trial. Lancet. 2008;372:449-456.
43. Ya u JC, Phan AT, Chang DZ, et al. Effcacy of RAD001 (everolimus) and octreotide LAR in advanced low and intermediate grade neuroen-docrine tumors: Results of a phase II study. J Clin Oncol. 2008;26: 4311-4318.
44. Treiber G. mTOR inhibitors for hepatocellular cancer: A forward-moving target. Expert Rev Anticancer Ther. 2009;9:246-261.
45. Gabardi S, Baroletti S. Everolimus: A proliferation signal inhibitor with clinical applications in organ transplantation, oncology and cardiology. Pharmacotherapy. 2010;30:1044-1056.
46. Stallone G, Di Paolo S, Schena A, et al. Addition of sirolimus to cyclosporine delays the recovery from delayed graft function but does not affect 1-year graft function. J Am Soc Nephrol. 2004;15:228-233.
47. Albano L, Berthoux F, Moal MC, et al. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation. 2009;88:69-76.
48. Letavernier E, Legendre C. MTOR inhibitors-induced proteinuria: Mechanisms signifcance and management. Transplant Rev. 2008;22: 125-130.
49. Franz S, Tregeniter A, Hopfer H, Mihatsch M, Dickermann N. Tubular toxicity in sirolimus- and cyclosporine-based transplant immunosup-pression strategies: An ancillary study from a randomized controlled trial. Am J Kidney Dis. 2010;55:335-343.
50. Bertoni E, Bruschi M, Candiano G, et al. Post-transplant proteinuria associated with everolimus. Transplant Proc. 2009;41:216-217.
51. Cao W, Mohacsi P, Shorthouse R, Pratt R, Morris RE. Effects of rapamycin on growth-factor stimulated vascular smooth muscle cell DNA synthesis. Inhibition of basic fbroblast growth factor and platelet-derived growth factor action and antagonism of rapamycin by FK506. Transplantation. 1995;59:390-395.
52. Schuurman HJ, Pally C, Weckbecker G, Schuler W, Bruns C. SDZ RAD inhibits cold-ischemia induced vascular remodeling. Transplant Proc. 1999;31:390-395.
53. Neumayer HH. Introducing everolimus (Certican. in organ transplantation: An overview of preclinical and early clinical developments. Transplantation. 2005;79(9 Suppl):S72-S75.
54. Delgado JF, Manito N, Segovia J, et al. The use of proliferation signal inhibitors in the prevention and treatment of allograft vasculopathy in heart transplantation. Transplant Rev (Orlando). 2009;23:69-79.
55. Shimohama T, Ako J, Yamasaki M, et al. SPIRIT III JAPAN versus SPIRIT III USA: A comparative intravascular ultrasound analysis of the everolimus-eluting stent. Am J Cardiol. 2010;106:13-17.
56. Eisen HJ, Murat Tuzcu E, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349:847-858.
57. Vigano M, Tuzcu M, Benza R, et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplant recipients: A 24-month analysis. J Heart Lung Transplant. 2007;26:584-592.
58. Lehmkuhl HB, Arizon J, Viganò M, et al. Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. Transplantation. 2009;88:115-122.